← Search & browse all drugs

triclabendazole

P02BX04

Forms & Strengths

Oral tablets: 250 mg

Adult Dosing

Fascioliasis: 10 mg/kg orally twice daily, administered 12 hours apart, given on the same day
Severe or resistant fascioliasis: 20 mg/kg/day divided into two doses on two consecutive days (total 40 mg/kg)

Pediatric Dosing

Children 6 years of age and older: 10 mg/kg orally twice daily, administered 12 hours apart on the same day (same as adult dosing)
Children under 6 years of age: Safety and efficacy have not been established

Indications

Treatment of fascioliasis caused by Fasciola hepatica and Fasciola gigantica in patients 6 years of age and older

Mechanism of Action

Benzimidazole derivative that binds to tubulin, inhibiting microtubule polymerization and leading to disruption of intracellular transport, impairment of the parasite's uptake of glucose, and ultimately death of the fluke

Contraindications

Known hypersensitivity to triclabendazole, other benzimidazoles (e.g., albendazole, mebendazole), or any components of the formulation

Adverse Reactions

Abdominal pain
Headache
Dizziness
Nausea
Urticaria
Night sweats
Hyperhidrosis
Chest pain
Transaminase elevations
Prolongation of the QT interval

Drug Interactions

CYP1A2 substrates: Triclabendazole is an inducer of CYP1A2; caution and monitoring required when co-administered with narrow therapeutic index CYP1A2 substrates (e.g., theophylline)
QT-prolonging drugs: Co-administration with other drugs that prolong the QT interval may increase the risk of ventricular arrhythmias

Curated Content: Needs Vetting Before Put to Clinical Use